Ilyang Pharmaceutical일양약품
007570 · KOSPI · ₩007570 · 일양약품
₩6,960▲ ₩50 (0.72%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩272B | ₩269B | ₩267B | ₩248B | ₩371B |
| Cost of sales | ₩156B | ₩157B | ₩150B | ₩139B | ₩167B |
| Gross profit | ₩116B | ₩111B | ₩116B | ₩108B | ₩204B |
| Operating income | ₩5B | ₩11B | ₩16B | ₩14B | ₩41B |
| Net income | ₩7.1B | ₩11B | −₩2B | ₩20B | ₩26B |
| Net income to shareholders | ₩6.9B | ₩10B | −₩2.4B | ₩19B | ₩14B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩457B | ₩431B | ₩393B | ₩403B | ₩494B |
| Current assets | ₩148B | ₩125B | ₩124B | ₩118B | ₩204B |
| Cash and equivalents | ₩24B | ₩4.3B | ₩3.4B | ₩7.2B | ₩48B |
| Total liabilities | ₩216B | ₩190B | ₩162B | ₩165B | ₩223B |
| Current liabilities | ₩171B | ₩157B | ₩139B | ₩145B | ₩198B |
| Borrowings | ₩126B | ₩93B | ₩66B | ₩71B | ₩96B |
| Total equity | ₩241B | ₩242B | ₩230B | ₩238B | ₩272B |
| Shareholders' equity | ₩238B | ₩238B | ₩227B | ₩238B | ₩272B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩12B | ₩5.6B | ₩15B | ₩5.9B | ₩67B |
| Capital spending | ₩5.7B | ₩38B | ₩5.9B | ₩3.9B | ₩13B |
| Free cash flow | ₩6.3B | −₩33B | ₩8.7B | ₩1.9B | ₩54B |
| Dividends paid | ₩2.9B | ₩3B | ₩3B | ₩3.9B | ₩8.8B |
Consolidated where available. Amounts in won.
Also known as: Ilyang Pharmaceutical / 일양약품 / 007570 / KRX:007570
Source: KRX statistical information